Myeloma Research News

January 17, 2022January 17, 2022

Model May Better Classify Multiple Myeloma and Relapse Risks

A model that may better classify multiple myeloma (MM) using genetic sequence data from hundreds of patients has been developed. The model can identify specific genes and genetic alterations responsible ... Read more

January 10, 2022January 10, 2022

Janssen Seeks FDA Approval of Teclistamab for RRMM

Myeloma Research News

Janssen is seeking the approval of its investigational therapy teclistamab in the U.S. for people with relapsed or refractory multiple myeloma (RRMM). “Despite all the gains that have been made ... Read more

December 20, 2021December 20, 2021

Xpovio Conditionally Approved in China for Heavily Treated Patients

Myeloma Research News

China’s National Medical Products Administration (NMPA) has conditionally approved a combination of Xpovio (selinexor) and the corticosteroid dexamethasone to treat adults with relapsed or refractory multiple myeloma (RRMM) who received ... Read more

December 13, 2021December 13, 2021

Cilta-cel Approval Requested in Japan for Heavily-treated Myeloma

Myeloma Research News

Janssen has submitted an application to regulators in Japan seeking the approval of ciltacabtagene autoleucel, an investigational CAR T-cell therapy also known as cilta-cel, to treat relapsed or refractory multiple ... Read more

December 6, 2021December 6, 2021

FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients

Myeloma Research News

The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple ... Read more

November 29, 2021November 29, 2021

GC012F, CAR-T Cell Therapy Candidate, Granted FDA Orphan Drug Status

Myeloma Research News

Gracell Biotechnologies’ investigational new treatment for multiple myeloma, GC012F, has been named an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status is intended to encourage ... Read more

November 22, 2021November 22, 2021

1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100

Myeloma Research News

Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100. The trial (NCT04634435) seeks to recruit 25 adults with newly diagnosed ... Read more

November 15, 2021November 15, 2021

Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

Myeloma Research News

The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose ... Read more

November 8, 2021November 8, 2021

Blenrep-nirogacestat Combo Moves to Dose-testing Phase 2 of Trial

Myeloma Research News

After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test a combination of Blenrep (belantamab mafodotin) with nirogacestat in adults ... Read more

November 3, 2021November 3, 2021

FDA Expects Decision on Cilta-cel Approval by February 2022

Myeloma Research News

The U.S. Food and Drug Administration (FDA) is expected to decide by the end of February whether or not to approve ciltacabtagene autoleucel, known as cilta-cel, an investigational CAR T-cell ... Read more

February 22, 2021February 22, 2021

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

Myeloma Research News

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as ... Read more

February 19, 2021February 19, 2021

C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

Myeloma Research News

C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food and Drug Administration (FDA) approved ... Read more

February 17, 2021February 17, 2021

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

Myeloma Research News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study ... Read more

February 15, 2021February 16, 2021

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

Myeloma Research News

Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to exploratory analyses of two Phase ... Read more

February 12, 2021February 12, 2021

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

Myeloma Research News

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior ... Read more